Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00916149 · ClinicalTrials.gov registry record · NA

Cognitive Effects of Treatment of Interictal Discharges

A NA study of Epilepsy, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
31
Enrollment target
1
Study location

NCT00916149 is a NA study of Epilepsy that has completed, run by Massachusetts General Hospital. The registered enrollment target is 31 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00916149, a NA study of Epilepsy, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
31 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if levetiracetam (for patients with focal seizures) or lamotrigine (for patients with generalized seizures) reduces the occurrence of interictal discharges. The study investigates the possible correlation between reduction of interictal discharges and improved cognitive performance.

Conditions Studied

Interventions

  • DRUG Lamotrigine
  • DRUG levetiracetam

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2007-01
Est. Completion 2012-10
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT00916149

The ClinicalTrials.gov registry entry for NCT00916149 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (97% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Lamotrigine is the first listed.

NCT00916149 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT00916149 about?

NCT00916149 is a clinical study titled "Cognitive Effects of Treatment of Interictal Discharges". The purpose of this study is to determine if levetiracetam (for patients with focal seizures) or lamotrigine (for patients with generalized seizures) reduces the occurrence of interictal discharges. The study investigates the possible correlation between reduction of interictal discharges and improv...

What is the current status of trial NCT00916149?

This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2007-01. Estimated completion is 2012-10.

What conditions does trial NCT00916149 study?

This clinical trial studies the following conditions: Epilepsy.

What interventions are being tested in trial NCT00916149?

The interventions under investigation include: Lamotrigine (DRUG), levetiracetam (DRUG).

Who is sponsoring clinical trial NCT00916149?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00916149 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epilepsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.